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Adrian V. Hernandez, MD, PhD,c Sean P. Lyden, MD,a and Daniel Clair, MD,a Cleveland, Ohio
Objective: Little data exist to support the durability of thoracic endovascular repair during prolonged periods of
follow-up. This study examines the durability and long-term results with the Zenith TX1 and TX2 thoracic devices (Cook
Inc, Bloomington, Ind) in high-risk patients.
Methods: Data were collected prospectively from 2001 to 2007 on high-risk patients who presented with thoracic
aneurysms, chronic aortic dissection, or fistulas treated with a Zenith thoracic device. Surgical modifications of proximal
or distal landing zones were performed when necessary. Computed tomography follow-up scans were performed before
discharge, at 1, 6, and 12 months, and yearly thereafter. Three-dimensional reconstruction software with central line of flow
measurements was used to assess aortic morphologic characteristics. Kaplan-Meier analysis was used to assess survival, freedom
from reintervention, predictive factors of poor outcome, and morphologic changes, including aneurysm sac behavior.
Results: A total of 160 patients (44% women; mean age, 70) were treated for 130 thoracic aneurysms, 25 aortic dissections
with aneurysm, 2 fistulas, and 3 symptomatic or aortic ruptures, or both. Mean follow-up was 36 months, and aneurysm
size was 67 mm. Seventy-five patients (47%) had undergone prior aortic aneurysm repair. Surgical modifications were
required to create adequate landing zones in 33% patients, including 28 elephant trunk/arch reconstruction, 22
carotid-subclavian bypasses, and seven visceral vessel bypasses. Iliac conduits were required in 31 patients. Early mortality
(<30 days) occurred in 11 patients (6.9%). Overall mortality at 1 year was 16%. Aneurysm sac increase (>5 mm) requiring
intervention was observed only in one patient in the settings of component separation and type III endoleak that was
treated; the sac is now stable. Twenty-seven endoleaks were detected in 25 patients: 15 primary endoleaks (9.4%) <30
days and 12 secondary endoleaks (7.5%) >30 days. Secondary interventions were required in 42 patients (26%).
Conclusion: Endovascular treatment of thoracic aortic pathologies with the Zenith TX1 and TX2 devices is feasible and
durable. The mid- to long-term results are encouraging, with acceptable low reintervention rates and with good survival
within high-risk patients. ( J Vasc Surg 2008;48:54-63.)The use of endovascular stent grafts has revolutionized
the management of thoracic aortic pathologies. This mo-
dality is considered safe and effective at preventing aneurysm
rupture through short- and intermediate-term follow-up
studies; however, little extended follow-up data exist in the
published literature.1-6 The ascribed benefits of such treat-
ment options center on the lack of need for a thoracotomy,
extensive tissue dissection, and aortic cross-clamping. The
acute physiologic insult is less compared with conventional
open surgical repairs, allowing physicians to treat patients
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54considered too ill for traditional surgery and lessening the
risk of morbidity and mortality for those who are candidates
for either type of repair.7
Although some randomized trials support a long-term
benefit for infrarenal aneurysm repair,8 similar studies have
not been conducted with thoracic aortic pathology. The less
frequent appearance of thoracic disease compared with infra-
renal aneurysms offers some explanation; however, thoracic
aortic disease may arise from a variety of etiologies, each
having marked differences in outcome expectations (divertic-
ulum, aneurysms, and aortic dissection). These factors con-
found the ability to design, analyze, and report outcomes for
thoracic endovascular aneurysm repair (TEVAR).
All published studies either represent series of treated
patients or controlled trials where endovascular patients are
compared with a mixture of retrospective and prospective
surgical patients serving as a control population. Despite
the lack of optimal data, insight with respect to the benefits
and challenges of endovascular repair can be gained from a
detailed evaluation of clinical experiences. Concerns spe-
cific to the durability of endovascular repair include device
migration, late endoleak occurrence, component separa-
tion, and device integrity, all of which can only be assessed
in the setting of detailed and extensive clinical and radio-
graphic follow-up. The aim of this analysis is to examine the
extended follow-up of TEVAR using the Zenith TX1 and
ercen
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patients with descending thoracic aortic pathology.
METHODS
Data were accumulated under the guidance of a spon-
sored investigational device exemption that began in Feb-
ruary 2001 and ended in August 2007 (for the purpose of
this analysis). Enrolled patients were considered to be at
high risk for open surgical repair and signed an informed
consent form approved by the Cleveland Clinic Institu-
tional Review Board. Inclusion criteria and procedural de-
tails have been previously published.4
Adherence with the latest version of the endovascular
grafting reporting standards was attempted whenever
possible, with the notable exception of device migration,
which was analyzed in a manner previously described by
our group.9 All imaging data are reported using three-
dimensional (3D) analysis tools (multiplanar reconstruc-
tions, centerline of flow calculations, and surface render-
ing algorithms) when appropriate. Paraplegia was
defined as a complete deficit or inability to ambulate as a
result of spinal cord ischemia at the time of hospital
discharge or death. Operative time was defined as the
time when the skin incision was made to skin closure.
The device design has also been previously described;
however, two fundamental delivery system changes were
made during patient enrollment. The first alteration was
implemented to diminish sheath kinking. The standard
polytetrafluoroethylene sheath that was used on early de-
vices was replaced with Flexormaterial (Cook Inc), which is
a braided sheath with hydrophilic coating. Although this
improved some delivery characteristics, the rigidity of the
system remained a challenge. Given that the device is
delivered by insertion over a stiff wire, it would be optimal
to match the device flexibility with that of the insertion
wire. To accomplish this, the inner cannula through which
Table I. Demographics and aneurysm type
Variablea
Thoracic aneurysm
(n  131)
Age, yearsb 74 (68-79)
Menb 68 (52)
Prior aortic repairb 62 (47)
Aneurysm size, mean mmb 66 (58-76)
Surgical modification of the proximal neck 39 (30)
Visceral bypass 7 (5)
Iliac or aortic conduit 29 (22)
Anesthesia
General 41 (31)
Regional 88 (67)
Local 2 (2)
Surgical time, min 142 (96-187)
Contrast volume, mL 135 (105-185)
Fluoroscopy total time, min 16 (12-24)
Estimated blood loss, mLb 300 (200-600)
aContinuous variables are given as median (interquartile range, 25th-75th p
bP  .05 for comparison among groups; caution with small numbers.the stiff wire passes was changed from a tube of stainlesssteel to a nitinol cannula. This change markedly improved
the flexibility and was termed “super-flex,” but later re-
named to Z-Track Plus.
Follow-up and statistical analysis. Clinical, radio-
graphic, and laboratory follow-up were obtained before
discharge, at 1, 6, and 12 months, and yearly thereafter.
Mortality data was supplemented by querying the Social
Security Death Index quarterly and follow-up phone calls
when necessary. Data were entered into an Oracle Clinical
database (Oracle Corp, Redwood Shores, Calif) for the
purposes of compliance and edit tracking. Kaplan-Meier
techniques, univariable, multivariable analysis, and logistic
regression were used in an effort to relate outcomes with
preoperative factors. Statistical analyses were performed
with SAS software (SAS Institute, Cary, NC).
RESULTS
A total of 160 patients (44% women), with a mean age
of 70 years, were treated. Indications for intervention ac-
cording to the disease etiology included thoracic aneurysms
in 130, chronic aortic dissection with aneurysm in 25,
aortobronchial fistulas in 2, and symptomatic or aortic
ruptures, or both, in 3. Mean follow-up was 36 months
(range, 1 day-78 months), and mean aneurysm size was 67
mm. The average length of aorta covered by the stent graft,
as measured by a centerline of flow analysis, was 219 mm.
Despite a liberal minimum proximal and distal neck length
of10 mm, 33% of patients required surgical modification
of the implantation landing site. Elephant trunk grafts were
placed in 28 patients, 22 had preoperative carotid–subcla-
vian bypasses, and seven required visceral bypasses. Two
patients who required elephant trunk grafts also required
carotid–subclavian bypass, and two underwent visceral ves-
sel bypass as well. Iliac conduits for access were required in
31 patients (19%). At least one prior aortic repair had
already been done in 75 patients (47%) in this cohort
hronic dissection aneurysm
(n  25)
Other
(n  4)
Total
(n  160)
55 (46-71) 74 (62-80) 73 (66-79)
17 (68) 4 (100) 89 (56)
12 (48) 1 (25) 75 (47)
59 (54-68) 75 (62-82) 65 (57-75)
8 (32) 1 (25) 48 (30)
0 0 7 (4)
2 (8) 0 31 (19)
9 (36) 4 (100) 54 (34)
15 (60) 0 103 (64)
1 (4) 0 3 (2)
115 (95-195) 162 (139-178) 140 (96-190)
132 (90-170) 175 (132-190) 137 (105-185)
15 (9-18) 19 (17-25) 16 (12-23)
200 (100-350) 225 (131-350) 300 (195-562)
tile) and categoric variables as number (%).C(Table I).
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patients (6.9%). Two patients each died of primary cardiac
issues, including ventricular tachycardia in one andmyocar-
dial infarct in one, and cerebrovascular accident (CVA).
Two patients died of bleeding, one resulting from contin-
ued bleeding from an aortoesophageal fistula, which was
the primary indication for TEVAR; in the second patient, a
coagulopathy developed relating to a ruptured iliac artery
during delivery complications. Two died of sepsis (related
to a perforated diverticulum in 1 and as a result of uncon-
trolled fungemia in 1), and one patient each died of pul-
monary edema, multisystem organ failure, and an undefined
cause. Overall survival was 84%, 78%, 73%, 70%, and 70% at
12, 24, 36, 48, and 60 months, respectively (Fig 1 and Table
II).
Neurologic complications. Paraplegia occurred in
five patients (3.1%), three of which died during the periop-
erative period before any significant neurologic recovery. A
single patient recovered completely 6 months, and the
remaining patient had a persistent unilateral lower extrem-
ity deficit. All of the patients who presented a neurologic
deficit had extensive aortic coverage. The mean (SD)
length of the aorta covered in patients who had a spinal
cord ischemic insult was markedly greater then the length
of covered aorta in patients without deficits, at 219 (68.45)
mm vs 315 (44.09) mm (P  .001). Three of the five
patients also had complications such as iliac rupture in the
setting of Ehlers-Danlos disease, sepsis, or renal failure.
Associated risk factors observed in patients with paraplegia
included single internal iliac arteries and prior abdominal
aortic aneurysm (AAA) repair in four of the five patients,
perioperative hypotension in two, and left subclavian artery
coverage in two, although both had undergone carotid
subclavian bypass before TEVAR.
During the perioperative period, five patients (3.1%)
presented with CVAs and four died. Two patients died
early, at 10 and 25 days, and two others died after an
additional stroke at 93 and 375 days. Of interest, four of the
Fig 1. Overall mortality (thick line) and aneurysm-related moral-
ity (thin line) were assessed using a Kaplan-Meier analysis, and the
error bars denote the 95% confidence intervals (CI).five CVAs involved the posterior circulation and one thefrontoparietal cortex. Three of the five patients had exten-
sive aneurysmal disease of the aortic arch and underwent
staged carotid–subclavian bypasses. The single long-term
survivor of a CVA had presented with a ruptured thoracic
aneurysm and was treated with an urgent carotid–subcla-
vian bypass graft, followed by stent graft placement at the
same setting. This patient sustained a posterior circulation
stroke, recovered significantly, and was ultimately dis-
charged with warfarin therapy. The two other patients who
survived their initial strokes (1 posterior circulation, 1
frontoparietal cortex) sustained neurologic deficits during
balloon inflation in the arch while undergoing TEVAR
with regional anesthesia. Both recovered partially, had prior
carotid–subclavian bypasses, and were discharged with as-
pirin therapy. One died as a result of a second stroke that
affected the same cerebrovascular distribution, and the
other died of a ruptured subclavian aneurysm in the setting
of a properly placed endograft, as determined by autopsy.
Secondary procedures. Secondary interventions were
required in 42 patients (26%). Indications for reinterven-
tion specifically related to long-term issues with the treat-
ment or device include the 9 endoleaks, 2 aortobronchial
fistulae (1 was a recurrence of an aortobronchial fistula that
represented the initial treatment indication; the second
occurred de novo during follow-up), 1 aneurysm sac
growth, 3 component separations, 1 compressed stent
within an elephant trunk graft, and 1 patient with what was
perceived to be a tenuous proximal sealing segment in the
absence of an endoleak. Endovascular techniques were used
to treat all but one patient. In the surgically treated patient,
who had a persistent type I proximal endoleak, we placed an
elephant trunk graft proximally and combined the elephant
trunk graft with the endovascular repair distally using a
second thoracic component. This was accomplished suc-
cessfully. The breakdown of secondary interventions and
life-table analysis of freedom from requiring a secondary
intervention are presented in Fig 2 and Tables II and III.
Sac size and endoleaks. Aneurysm sac increase (5
mm) was observed in only two patients (Table IV). One
patient had aneurysm growth noted at the 1-year follow-up
visit, without evidence of endoleak or compromised fixa-
tion. She was monitored, and the aneurysm had decreased
in size at her 2-year visit. She is now 3 years after treatment,
without evidence of sac expansion. Only one other patient
had sac size increase that was detected at 4 years in the
setting of a type III endoleak resulting from component
separation. The patient underwent placement of an addi-
tional component to eliminate the endoleak and has not
had further growth to date. Primary endoleaks (30 days)
occurred in 15 patients (9.4%), and late endoleaks (30
days) were noted in 12 patients (7.5%). Other endoleaks
detected were 10 type I (7 primary, 3 secondary), 14 type II
(7 primary and 7 secondary), as well as 3 type III (1 primary
and 2 secondary). Two patients had endoleaks with two
separate causes. The first patient had a primary type I
endoleak, which was treated with a secondary intervention
perioperatively, and then presented with a late type II
endoleak, which has been observed. The second patient
ment or visceral bypass, or both.
repair, underwent treatment of the distal portion first, and subsequently was
treated for the proximal dissection.
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ponent separation and aneurysm growth were noted, thus
prompting a secondary intervention. Freedom from en-
doleaks is shown in Fig 3.
Migration. Migration was assessed by centerline of
flow distances from fixed landmarks (left common carotid
and celiac arteries), where 14 patients had 10 mm of
distance change throughout follow-up. Any patient with
detected changes of baseline central line length measure-
ments underwent further image assessment, primarily using
surface-rendering reconstruction to evaluate device posi-
tion in relation to local landmarks, such as hemaclips placed
on elephant trunk grafts or focal aortic calcifications.9
These analyses showed device movement (Fig 4) had oc-
curred in four patients (2.5%). The details of all migration
patients are listed in Tables II and V.
Device integrity. Barb fractures occurred in eight pa-
Table II. Outcomes of treatment classified in terms of pre
Outcome at follow-up
Overall
(n  160)
Th
A (n  10
Survival, %
1 year 84 83
2 years 78 77
3 years 73 68
4 years 70 64
5 years 70 64
Free of 2nd interventions
1 year 81 78
2 years 76 76
3 years 74 74
4 years 73 73
5 years 65 63
Free of migration
1 year 99 99
2 years 99 99
3 years 94 96
4 years 93 94
5 years 93 94
A, Endovascular graft; B, endovascular graft after elephant trunk graft place
Fig 2. Freedom from secondary intervention is shown in 160
patients with 72 months of follow-up.senting pathology
oracic (n  131)
Chronic dissections
(n  25)
Other
(n  4)4) B (n  27)
82 92 75
77 88 75
77 88 75
77 88 75
77 88 75
81 88 75
70 83 75
70 79 75
70 79 75
70 79 75
96 100 100
96 100 100
82 100 100
82 100 100
82 100 100tients (5%). Depending on device diameter, 12 or 13 barbsTable III. Description, type, and indications for 42
secondary interventions
Cause No. Open EVAR %
Related to DTA repair 19 45
Endoleak 9 1 8 21
Fistulaa 2 . . . 2 5
Aortic growth 1 . . . 1 2
Proximal dissectionb 1 . . . 1 2
Component-separation 3 . . . 3 7
Compressed-stent 1 . . . 1 2
LCC-LSA bypass 2 2 . . . 5
Inadequate seal 1 . . . 1 2
Procedure related 9 21
Thrombectomy 3 3 . . . 7
Hematoma evacuation 1 1 . . . 2
Leg ischemia 2 . . . 2 5
Brachial pseudoaneurysm 2 . . . 2 5
Rupture Iliac 1 1 . . . 2
Associated aneurysms/operations 14 21
AAA 7 1 6 17
Pseudoaneurysm 2 . . . 2 5
Ascending repair 2 2 . . . 5
Thoracoabdominal 1 . . . 1 2
Iliac 1 1 . . . 2
Carotid endarterectomy 1 1 . . . 2
Total 42 13 32 100
AAA, abdominal aortic aneurysm;DTA, descending thoracic aorta; EVAR,
endovascular aneurysm repair; LCC, left common carotid; LSA, left subcla-
vian artery.
Note: One patient had two indications for a secondary intervention.
aIn the two patients with fistulas, one had a recurrent aortoesophageal fistula
and the other had a de novo aortoesophageal fistula that was not seen on
angiogram but autopsy report revealed a fistulous track between esophagus
and the aorta just above the proximal stent graft.
bThis patient presented with a type A dissection before the endovascular
raphy
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barb fractures had only a single barb break (Fig 5). Frac-
tures were detected in three patients at 24months, in two at
36 months, and in three at 60 months. Only one of the
eight patients with barb fractures had evidence of device
migration, which was noted at 2 years of follow-up and
treated with a proximal extension (Table VI). The remain-
ing seven patients with barb fracture occurred in the setting
of stable fixation and sealing zones.
Patient accountability. Mortality data were available
for all patients throughout follow-up, as described inMeth-
ods. Clinical and imaging data were available for most
patients: 86% of patients had imaging and clinical informa-
tion available for analysis at 2 years, and 73% of the patients
Table IV. Aneurysm sac behavior during follow-up period
Sac behavior
1 month
(n  130)
6 months
(n  109)
1
(n 
Sac growth, % (No.)a 0% (0) 0% (0) 1%
Sac stable, % (No.) 65% (84) 43% (47) 31%
Sac shrink, % (No.) 35% (45) 57% (62) 68%
aNumbers in parenthesis reflect number of patients with a computed tomog
Fig 3. A, Kaplan-Meier life-table analysis shows of freedom from
primary endoleak and (B) secondary endoleaks.had complete imaging and clinical data as well at 5 years.DISCUSSION
Descending thoracic aortic aneurysms (TAA) are poten-
tially life-threatening diseases. The incidence and prevalence
of degenerative TAA have increased significantly,10-13 likely
as a result of increased awareness, screening, and an aging
population. The effect of this phenomenon will be an
increasing need for TAA intervention. Conventional open
resection and graft replacement of the pathologically al-
tered aorta has been considered to be the standard of
care.14,15 However, even in centers of excellence where
great strides have been achieved with respect to the devel-
opment of new surgical techniques and methods of patient
management, the morbidity and mortality rates for open
TAA repair remain high.16-19 A considerable population of
patients with thoracic aortic pathology are refused open
surgical repair as a result of comorbid illnesses and ulti-
mately die of TAA rupture.
TEVAR has emerged as a treatment option for patients
amenable to open repair and those considered too ill for
open repair.4,5,20-23 Several published studies have fol-
lowed the initial published report by Dake et al3 in 1994.
Despite some study design weaknesses, the first completed
comparative multicenter trial demonstrated convincing ev-
idence of superiority of TEVAR vs open surgery with
respect to both survival and morbidity.7,24 Yet, the longev-
ity of the endovascular repair (migration of device and
endoleaks) remains controversial, may depend on the eti-
ology of the disease and the specific portion of the anatomy
treated, and requires further elucidation.
The etiology of the disease, extensiveness of the in-
volved aorta, patient selection, and procedural planning are
paramount to the success of TEVAR. Simple vs complex
anatomy and straight healthy landing zones vs tortuous
diseased aorta all have marked implications on the expected
outcome. Unquestionably, endovascular procedures are
less invasive than open surgical TAA repair; yet even
TEVAR is associated with a relatively high perioperative
mortality rate. Despite stratification of a variety of comor-
bidities, true predictors of poor outcome were not possible
in this series given the limited number of patients and the
diversity of preoperative risk factors, including age, TAA
size and etiology, pulmonary dysfunction, cardiac dis-
ease, staged hybrid procedures, and chronic renal insuf-
ficiency.
These issues bespeak to the importance of clinical judg-
ment required to have a successful TEVAR program. A
)
2 years
(n  82)
3 years
(n  48)
4 years
(n  24)
5 years
(n  18)
0% (0) 0% (0) 4% (1) 0% (0)
) 28% (23) 27% (13) 38% (9) 17% (3)
) 72% (59) 73% (35) 58% (14) 83% (15)
scan in that follow-up periodyear
106
(1)
(33
(72number of patients were evaluated for treatment and not
the d
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of physiologic or anatomic challenges. The outcome of
such patients is the subject of a separate study. In contrast
with other series, our clinical protocol did allow for the
treatment of patients with very short and otherwise chal-
Fig 4. A, A three-dimensional (3D) reconstruction of a
cular completion of an elephant trunk graft. The pacer w
indicated by the small arrow. Distally, the device was depl
a polyester strip to create a landing zone in a patient deem
arrow). B, Same patient, 3D reconstruction CT scan at
position (arrow) enlargement of the wrapped segment,
stent through the wrap and into the aneurysm. Note, no
to the abnormal aorta below the level of the stent graft.C
the external aortic wall (arrows) caused by migration oflenging landing zones, markedly tortuous anatomy, andaneurysms elsewhere in the aorta, as well as the liberal use of
iliac/aortic conduits. Hybrid procedures, such as the place-
ment of elephant trunk grafts,25 were frequently used in
preference to reliance on a compromised sealing or fixation
region but were not possible in all patients. Retrospective
puted tomography (CT) scan demonstrates an endovas-
ttached near the distal end of the elephant trunk graft is
into an aneurysmal segment that had been wrapped with
able to tolerate an open thoracoabdominal repair (large
-month follow-up demonstrates a stable proximal dense
endoleak, and proximal migration (circle) of the distal
were used on the distal fixation system for fear of injury
nified view of previous image demonstrates scratches on
evice.com
ire a
oyed
ed un
the 6
distal
barbs
,Maganalysis of preoperative imaging studies of the four patients
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fixation zones, implying that device placement was planned
into unhealthy aorta. These regions demonstrated evidence
Table V. Patients diagnosed with device migration based
on central line of flow and surface rendered analyses
Date of
event
Stent
Secondary
intervention OutcomeNo. Type Migrated
2 years 1 TX1 Distal Yes OK
3 years 1 TX1 Proximal Yes OK
1 year 1 TX1 Proximal No Withdrew
from study
1/2 year 3 TX2 Distal Pending Pending
Fig 5. A and B, Radiographs in different projections demon-
strate a single barb fracture (circle and arrow) first noticed at 2
years follow up.of aortic dilation, likely resulting in inadequate fixationstrength that most probably contributed to the observed
migration.
When patient were amenable to additional procedures,
migration cases were treated with secondary interventions
intended to bring the fixation zone into healthy aorta by
using either fenestrated devices or extra-anatomic bypasses,
followed by endograft extensions. Obviously, to prevent
this, we would recommend planning the procedure such
that the proximal and distal fixation and sealing zones exist
in healthy aorta. Yet, the assessment of the health of the
aorta is far from a pure science.
We currently rely on the appearance of the intended
fixation zones on a stretched centerline of flow reconstruc-
tion or a curved planar reconstruction. Tapering diameters,
nonparallel walls, and debris or thrombus lining the wall are
generally considered to be unhealthy. These observations
were exceptionally difficult to make on 2D imaging studies
and really require 3D imagemanipulation for proper assess-
ment. Ultimately, it is likely that the choice of landing
zones is the most important component of procedural
planning. In addition to the status of the aortic wall, the
location with respect to tortuosity and aortic branches must
be considered. After the establishment of a plan for fixa-
tion/sealing regions, the length of the intervening segment
was used to dictate the size and number of components
required to complete the repair, a factor that had implica-
tions for the risk of neurologic complications.
Catastrophic neurologic complications, paraplegia and
strokes, have been reported in up to 18% patients undergo-
ing TEVAR.26 Although the incidence of spinal cord isch-
emia (SCI) for thoracic stent grafts may compare favorably
with open surgical repairs, it is likely that the patient pop-
ulations differ, rendering firm conclusions suspect to bias.
Obviously, it is not possible to reimplant intercostal arteries
during TEVAR, but the physiologic derangements appear
to be less than with open surgery. Thus, there is a trade-off
of risks, with evidence of SCI occurring in both groups.
It is an interesting observation that four of the five
patients with SCI in our series presented with prior AAA
repair and compromised internal iliac circulation in the
context of extensive aortic coverage.27 In addition, most
Table VI. Patients identified with single barb fractures
along with the type of device, timing, and association
with any clinical events
Date of event
Stent
Barb fractures,
No. MigrationNo. Type
5 years 1 TX1 1 . . .
5 years 1 TX1 1 Yes
3 years 1 TX1 1 . . .
5 years 1 TX1 1 . . .
3 year 2 TX1 1 . . .
2 years 2 TX2 1 . . .
2 years 2 TX2 1 . . .
2 years 2 TX2 1 . . .patients with observed deficits required coverage of the left
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fused by a left carotid–subclavian bypass before implanta-
tion of the endograft in an effort to mitigate the effect of
retrograde vertebral perfusion of the arm on SCI. Thus in
our series, the left subclavian coverage was more likely a
marker for extensive aneurysmal disease rather then as a
source of steal for spinal cord perfusion.
The immediate management of patients presenting
with SCI is critical. We used spinal drainage to 10 cm H2O
in patients we considered to be at a relatively high risk for
SCI (extensive coverage, prior AAA repair, or compro-
mised internal iliac circulation). Should SCI symptoms
manifest, the spinal drainage is increased by dropping the
cutoff from 10 cmH2O to 5 cm or 0 until resolution of the
neurologic symptoms is appreciated. Furthermore mean
arterial pressures were maintained at 90 mm Hg, prefer-
ably without the use of vasoconstrictors that may detrimen-
tally effect the collateral perfusion of the anterior spinal
artery by constricting the small pelvic, lumbar, and inter-
costal vessels. Reversible deficits were observed in a few
patients, and suchmaneuvers limited the symptoms to24
hours; however, we are unsure whether such symptoms
would have abated without these adjunct therapies.
Several reports have noted that both open and endo-
vascular patients are at risk for stroke, yet the mechanism by
which this complication occurs likely differs. Strokes after
open surgery may be attributed to embolic events that
occur with the placement of proximal cross-clamps but may
also result from hypotension and hypoperfusion if circula-
tory arrest is used during the proximal reconstruction.
Embolic CVAs have been linked with instrumentation of
the aortic arch.4,7
In two patients in our series who received regional
anesthesia, emboli occurred after arch ballooning done in
an effort to force the graft to conform to the lesser curva-
ture. The results of ensuing cerebral angiography did not
prompt neurointerventional rescue in either case. Subse-
quent computed tomography demonstrated multiple in-
farcts within the posterior circulation in both patients,
implying a diffuse embolic process. Two of the three pa-
tients who survived to hospital discharge after TEVAR
complicated by CVA ultimately died of strokes in the same
cerebrovascular distribution. Did the arch ballooning that
occurred in these two patients render plaques in the region
unstable, prompting secondary CVAs? Was a region of
turbulent flow created in the region of the proximal en-
dograft or left subclavian artery? Should a more aggressive
anticoagulation regimen be used in such circumstances?
These questions will require further investigation, which
will require pooling of patients with such complications
owing to the relatively low incidence of this complication.
Why is the posterior cerebral vasculature so promi-
nently affected? It seems logical that embolic debris would
migrate to this territory given the proximity of the en-
dograft placement to the vertebral artery. The use of cere-
bral protection during arch TEVAR has been suggested.
However, given the location of strokes in our series, it
would seem prudent to protect all four vessels feeding theintracranial circulation rather than the internal carotids
only. This would add considerable complexity to the pro-
cedure and likely create problems related specifically to the
embolic protection devices. Yet this complication remains
devastating and, in our series, associated with a very high
mortality.
Prompt treatment of type I and III endoleaks has been
advocated to prevent rupture.7,28 The management of type
II endoleaks, particularly in the thoracic aorta, has not been
fully elucidated; however, observation of these leaks is the
rule rather then the exception.28
Migration has also been the subject of some contro-
versy after TEVAR. There appears to be less debate about
device migration in the abdominal aorta.29 This phenom-
enon is less well-defined in the thoracic aorta. The Talent
(Medtronic/AVE, Santa Rosa, Calif) investigators30 de-
fined migration as a 5 mm increased in the distance
between the proximal covered part of the stent and left
subclavian artery, both at implantation and during follow-
up, yet they did not use 3D imaging studies to detect
movement. The published TAG (W. L. Gore & Assoc.
Flagstaff, Ariz) core laboratory data31 noted a 3-year free-
dom from migration of 83% but also relied on 2D studies
with a variable z-plane resolution for analysis. We used
much more rigorous methods of migration assessment,
which we previously described.9
Although the use of active fixation mechanisms may
help to discourage migration, the graft still requires the
aorta to remain at a stable diameter within the sealing
zones. We observed migration in four patients: two were
related to distal migration of proximal stents, and two had
proximal migrations of distal stents. It is interesting to
evaluate the specifics of the migration cases. The distal
stents that migrated involved implants that did not have
distal active fixation mechanisms like those used in TX2D
devices. One of the migrations occurred in the setting of a
thoracoabdominal aneurysm where a polyester wrap was
placed around an aneurysmal supraceliac aorta during the
placement of an elephant trunk graft to “create” a landing
zone, which ultimately proved to be unstable (Fig 4). Both
patients with migration of the proximal stents, when the
preoperative films were retrospectively analyzed with 3D
tools, had unhealthy aortic regions where the initial sealing/
fixation systems were deployed.
Life-table analysis of this patient series estimates that 93%
of the patients will be free ofmigration at 5 years of follow-up.
It seems likely that with more extended follow-up data,
the incidence of migration will increase, adding impor-
tance to the detailed assessment of imaging studies at
each follow-up visit. Such image analyses are also helpful
to detect component separation. As the endovascular
device conforms to the morphology of the aneurysm, the
prosthesis generally lengthens to sit along the outer
curvature of the aortic wall throughout the thoracic
aorta. The increased prosthesis length must be derived
either through proximal or distal fixation system migra-
tion or loss of overlap between components. Should two
overlapped components separate such that a type III
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this phenomenon in three patients, one of which had
aortic growth that resolved after the addition of another
overlap component.
Other device integrity problems were notably uncom-
mon. No stent fractures or cases of fabric disruption oc-
curred. Barb fractures were noted in seven patients, one of
which was associated with migration. The cause and effect
of the barb fracture and migration is unknown. The lack of
aneurysmal growth after TEVAR with these devices in all
but one patient, who developed a component separation
that was treated and resolved, adds credence to the integrity
of the fabric and overall repair.
A single-center study such as this has both advantages
and limitations. Technical expertise and clinical judgment
go hand in hand with volume and experience, and thus,
these results are not representative of what may occur in a
multi-institutional study with similar patients. It is likely
that the patients treated in this series were anatomically
more complex than patients in other reports simply owing
to referral patterns.
A treatment bias exists, as in any nonrandomized study,
with regard to the choice of available devices. Multiple
studies occurred during patient enrollment whereby ana-
tomically challenging patients were enrolled into this trial.
However, with a single center and a well-developed re-
search infrastructure, we were able to ensure that 90% of
the patients had cross-sectional imaging data available at 2
years of follow-up, a level of patient accountability that to
our knowledge has not been reported in any other series. In
addition, all imaging studies were reviewed using a 3D
workstation by at least three individuals blinded to each
other’s interpretations. Although our mean follow-up was
just 3 years, with an upper limit of 6 years, these results
still represent intermediate-term follow-up, and longer-
term data are required.
CONCLUSIONS
The treatment of patients with thoracic pathology with
the Zenith TX1 and TX2 devices is associated with reason-
able intermediate-term results. The perioperative risks re-
main significant, and anatomic challenges still exist man-
dating the use of hybrid procedures in some circumstances.
The incidence of late complications is relatively low. Late
endoleak, component separation, and device integrity is-
sues were uncommon, despite detailed radiographic evalu-
ation in a study with excellent patient accountability. Mi-
gration was also rare and appeared to occur primarily when
the fixation and sealing segments of the grafts were placed
into relatively unhealthy aortas. Unquestionably, longer-
term follow-up is necessary in addition to the accumulation
of more patients with varying types of anatomy or disease
etiology. Further work in this area will improve our under-
standing of thoracic aortic disease, judgment regarding
patient selection, and choice of sealing and fixation zones.AUTHOR CONTRIBUTIONS
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